Ascentage Pharma Group International American Depository Shares (AAPG) vs Rapport Therapeutics (RAPP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rapport Therapeutics (RAPP) has outperformed Ascentage Pharma Group International American Depository Shares (AAPG) over the past year, gaining 10.3% versus a loss of 63.8%. Rapport Therapeutics is the larger company by market cap ($1.43 billion vs $1.36 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AAPG | RAPP |
|---|---|---|
| Share price | $14.55 | $29.85 |
| Market cap | $1.36B | $1.43B |
| 1-day change | -4.09% | -3.27% |
| YTD return | -44.55% | -1.62% |
| 1-year return | -63.83% | +10.31% |
| EPS (TTM) | $-2.26 | $-3.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-111.48M |
| 52-week high | $37.50 | $52.93 |
| 52-week low | $14.46 | $23.75 |
| Distance from 52-week high | -61.20% | -43.60% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +223.92% | +111.19% |
| Average volume | 6.37K | 359.60K |
| Shares outstanding | 93.39M | 47.98M |
| Employees | 828 | 84 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RAPP has outperformed AAPG by 74.1 percentage points over the past year.
About Ascentage Pharma Group International American Depository Shares
AAPG stock →Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation.
Health Care · Biotechnology: Pharmaceutical Preparations · 828 employees
About Rapport Therapeutics
RAPP stock →Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees
AAPG vs RAPP FAQ
Which is bigger, Ascentage Pharma Group International American Depository Shares or Rapport Therapeutics?
Rapport Therapeutics (RAPP) is larger, with a market capitalization of $1.43B compared with $1.36B for Ascentage Pharma Group International American Depository Shares (AAPG).
Which stock has performed better over the past year, AAPG or RAPP?
RAPP returned +10.31% over the past 12 months, compared with -63.83% for AAPG (price return, excluding dividends). Past performance does not predict future results.
Are Ascentage Pharma Group International American Depository Shares and Rapport Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.